Eurobio-Scientific SA

As of December 31, 2024, Eurobio-Scientific SA carries a market capitalization of 254.37M, placing it among publicly traded companies globally. Its enterprise value stands at 243.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eurobio-Scientific SA's next confirmed earnings release is scheduled for April 14, 2027.

As of December 31, 2024, Eurobio-Scientific SA has 10.03M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Eurobio-Scientific SA maintains a current ratio of 2.17, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 23, 2026, Eurobio-Scientific SA's stock has gained approximately 5.57% over the past 52 weeks. The 50-day moving average sits at 22.96, while the 200-day moving average is 22.58.

As of December 31, 2024, Eurobio-Scientific SA holds 23.07M in cash and equivalents against 12.57M in total debt, resulting in a net debt position of -11.28M. Total book value stands at 178.86M, with working capital of 48.24M providing operational flexibility.

Eurobio-Scientific SA's most recent stock split took place on September 1, 2017 with a 20:1 split ratio.